Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response.
about
Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma presenting in nasal cavity: a case report and review of literatureReview of the current targeted therapies for non-small-cell lung cancerCIViC databasePromising response of anaplastic lymphoma kinase-positive large B-cell lymphoma to crizotinib salvage treatment: case report and review of literatureAnaplastic lymphoma kinase-positive large B-cell lymphoma: Clinico-pathological study of 17 cases with review of literature.ALK-driven tumors and targeted therapy: focus on crizotinibCD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options.CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases.An update of ALK inhibitors in human clinical trials.ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern.Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base.Anaplastic lymphoma kinase-positive large B-cell lymphoma: description of a case with an unexpected clinical outcome.Reduction of leukemia cell burden and restoration of normal hematopoiesis at 3 months of crizotinib treatment in RAN-binding protein 2 (RANBP2)-anaplastic lymphoma kinase (ALK) acute myeloid leukemia.
P2860
Q26862702-FD4D7AF8-587B-403E-9C63-2C71F74EE11BQ27015079-9CA4C0CA-B800-4F58-BDBE-161140999F1EQ27612411-643214F1-012F-4F17-B376-FCF76FB532CEQ27853192-5A0F97CA-56B6-4E52-9E9C-AE7862A4F889Q33859852-4DFD5175-64E7-472D-B67B-BD8AE19C0972Q34414378-2A544007-7706-41DE-AD2E-EE9ED6473521Q34460823-46910D1D-0EC9-4363-B819-B7BF9F4ADA9BQ38605346-C5F5FD7B-4554-465E-B542-EB39116075CFQ38652927-F2D45A56-F7AF-4D8F-966A-793C2A11B6D0Q38701797-2751E7DE-8968-42B1-8E7D-913BF507421BQ47821848-CDE70EBE-C235-4AC9-8088-ACC5F551ADE5Q53089324-A4BC1228-3A2C-43CF-96DE-FA8C1F0E8E59Q54350933-2DC1A474-7D1F-4848-BE69-B8DA836BFF5B
P2860
Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Crizotinib in refractory ALK-p ...... rt with a short-term response.
@ast
Crizotinib in refractory ALK-p ...... rt with a short-term response.
@en
Crizotinib in refractory ALK-p ...... rt with a short-term response.
@nl
type
label
Crizotinib in refractory ALK-p ...... rt with a short-term response.
@ast
Crizotinib in refractory ALK-p ...... rt with a short-term response.
@en
Crizotinib in refractory ALK-p ...... rt with a short-term response.
@nl
prefLabel
Crizotinib in refractory ALK-p ...... rt with a short-term response.
@ast
Crizotinib in refractory ALK-p ...... rt with a short-term response.
@en
Crizotinib in refractory ALK-p ...... rt with a short-term response.
@nl
P2093
P356
P1476
Crizotinib in refractory ALK-p ...... rt with a short-term response.
@en
P2093
Anja Mottok
Bärbel Schädlich
Hans-Joachim Schmoll
Karin Jordan
Timo Behlendorf
P304
P356
10.1111/EJH.12240
P577
2014-03-01T00:00:00Z